Macular Degeneration Treatment Market size was valued at US$ 8,457.3 million in 2023, growing at a 7.3% CAGR from 2024 to 2030. Macular degeneration is a neurodegenerative ocular disorder that affects the part of the eye called the macula. Degeneration of the macula will result in loss of central vision. It grows when the capillaries around the fovea dilate and leak. This causes fluid build-up that impairs the reflection of light and results in progressive vision loss. It mainly affects the age of people between 50 and 60 years. This condition is characterized by night blindness, tunnel vision, and loss of central vision. It is also called age-related macular degeneration (AMD). The increasing aging population across the world, and the rising number of obese and cardiovascular patients, will propel the market growth during the forecast period. Additionally, the increasing population with retinal disorders and hypertension will also hike the market demand. Increasing smoking and foods containing saturated fats may lead to macular degeneration, which in turn expands the market size. The increasing burden of retinal disorders is driving market growth.

For instance, as per the research article titled "Prevalence and incidence of age-related macular degeneration in Europe: a systematic review and meta-analysis" by Jeany Q Li et al., in Europe, age-related macular degeneration (AMD) is the main cause of visual impairment and blindness. About 67 million people in Europe are affected by age-related macular degeneration (AMD), and due to the aging population, this number is expected to increase by 15% by 2050. Furthermore, increasing R&D activities led to developments such as the inception of CY-09, a new clinically proven drug to protect the macula from inflammation and could have less chance of the occurrence of dry AMD will further favor the market growth.  

Macular Degeneration Treatment Market Key Developments

• In September 2021, Novartis, a Swiss-based pharmaceutical company, acquired Arctos Medical for an undisclosed amount. The acquisition is witnessed to allow Novartis to provide treatments for patients with vision loss and leverage the potential of optogenetics as the basis of successful therapeutics.